Known targets — ChEMBL curated mechanism
ACHESCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL19470156 | 1.00 | LMNA (0.77) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL4165311 | 0.98 | LMNA (0.74) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL14813276 | 0.96 | LMNA (0.84) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL303216 | 0.96 | LMNA (0.77) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL2266761 | 0.96 | LMNA (0.77) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL17675382 | 0.96 | LMNA (0.77) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL872078 | 0.96 | LMNA (0.77) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL14662536 | 0.96 | LMNA (0.77) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL21835970 | 0.96 | LMNA (0.77) | LMNAPDE4AL3MBTL1USP2SLCO1B1 | |
| Gluconic Acid SCHEMBL5861529 | 0.96 | LMNA (0.77) | LMNAPDE4AL3MBTL1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10905744-B2 | Pharmaceutical formulations for the oral delivery of peptide drugs | CYPRUMED GMBH (AT) | 2021-02-02 | — | — | US | claimed |
| EP-3204045-B1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-12-05 | — | — | EP | claimed |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2018-10-04 | — | — | US | claimed |
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2017-10-26 | — | — | US | claimed |
| US-10905744-B2 | Pharmaceutical formulations for the oral delivery of peptide drugs | CYPRUMED GMBH (AT) | 2021-02-02 | — | — | US | disclosed |
| EP-3204045-B1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-12-05 | — | — | EP | disclosed |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2018-10-04 | — | — | US | disclosed |
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2017-10-26 | — | — | US | disclosed |
| EP-1684726-A4 | COMPOSITION AND METHOD FOR ENHANCING BIOAVAILABILITY | ALZA CORP (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1684726-A1 | COMPOSITION AND METHOD FOR ENHANCING BIOAVAILABILITY | ALZA Corporation (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005051358-A1 | COMPOSITION AND METHOD FOR ENHANCING BIOAVAILABILITY | ALZA CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-0907358-A2 | UNIFORM DRUG DELIVERY THERAPY | ALZA CORPORATION (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997037640-A2 | UNIFORM DRUG DELIVERY THERAPY | ALZA CORPORATION (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | SLC30A5, SLC30A6, SON | LMNA 4870/4885PDE4A 3670/4885L3MBTL1 4695/4885 |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | SLC30A5, SLC39A11, SLC30A6 | LMNA 4860/4885PDE4A 3414/4885L3MBTL1 4543/4885 |
| US-10905744-B2 | Pharmaceutical formulations for the oral delivery of peptide drugs | SLC30A5, SLC39A11, SLC30A6 | LMNA 4860/4885PDE4A 3414/4885L3MBTL1 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.